Display / advertising
The news now published is hard to beat and demonstrates the high scientific level on which the developments of InnoCan Pharma * (WKN: A2PSPW) are based.
The fact that ABX464 of the French company Abivax (A14UQC), which is basically based on microRNA technology, shows promising results in a number of inflammatory diseases that are being tested in clinical trials.
* Please note the following information on the conflicts of interest definitely existing at bullVestor with regard to this publication as well as our risk statements and our exclusion of liability
Subscribe to my free newsletter
Risk information and exclusion of liability
We expressly point out that we do not assume any liability for the content of external links.Each investment in securities is subject to risks. Political, economic or other changes may lead to significant price losses. This applies in particular to investments in (foreign) ancillary values as well as in small and microcap companies. Due to the low stock market capitalisation, investments in such securities are highly speculative and involve a high risk up to the total loss of invested capital. In addition, the shares presented at bullVestor are partly subject to currency risks.
The background information published by bullVestor for the German-speaking region, market assessments were prepared in compliance with Austrian and German capital market regulations and are therefore intended exclusively for capital market participants in the Republic of Austria and the Federal Republic of Germany. Other foreign capital market schemes have not been taken into account and do not apply in any way. BullVestor & APOs; s publications are exclusively for informational purposes and do not explicitly constitute a financial analysis, but are promotional texts of a purely advertising nature to the companies discussed in each case, which pay a fee for this purpose.
There is no consulting agreement between the reader and the authors or the publisher by the reference of the bullVestor publications. All information and analyses do not constitute a request, an offer or a recommendation for the purchase or sale of investment instruments or for other transactions. Any investment in shares, bonds, options or other financial products is, in some cases, subject to significant risks.
The editors and authors of the bullVestor publications are not professional investment consultants. Therefore, you must always be advised by a qualified specialist (e.g. through your house bank or a qualified consultant of your trust) when making your investment decisions. All information and data published by bullVestor comes from sources that we consider reliable and trustworthy at the time of creation. However, no liability can be assumed with regard to the correctness and completeness of this information and data.
The same applies to the assessments and statements contained in the analyses and market estimates of bullVestor. These were prepared with due care. Responsibility or liability for the accuracy and completeness of the information contained in this publication is excluded. All statements of opinion made reflect the current assessment of the authors, which may change at any time without prior notice. No warranty or liability is expressly assumed for the fact that the price or profit developments predicted in the bullVestor releases occur.
Information on conflicts of interest
The editors and responsible authors hereby declare that there are the following conflicts of interest with regard to the company in question in this publication at the time of publication:
Legal notice:
BullVestor Medien GmbHGutenhofen 44300 St. Valentin ÖsterreichTel: + 43 7435 54077-0Company number: FN275279yManaging Director and 100% owner: Helmut PollingerCourts stand: St. Pöltenkontakt [at] bullvestor.at- Werbung-
Values included: CA45783P1027
